72
Views
18
CrossRef citations to date
0
Altmetric
Review

Latest advances in the cannabinoids

Pages 1457-1476 | Published online: 06 Dec 2007
 

Abstract

The endocannabinoid system has received much attention in recent years as a source of therapeutic targets for a wide range of indications. This review covers advances made in the area of small molecule, non-cannabinoid modulators of the cannabinoid receptors CB1 and CB2 since July 2006. Under discussion are patents published in this period that disclose new compounds acting at either of the two confirmed cannabinoid receptors as agonists, antagonists or inverse agonists. The bulk of the material covered is in the area of CB1 antagonists and inverse agonists; however, there continues to be strong interest in the area of CB2 agonists, where pain is presently the major indication. New indications for all areas have been claimed as the expression pattern of the receptors continues to be expanded. The discovery of a potential third cannabinoid receptor only increases both the complexity of the field and the potential for providing therapeutic agents.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.